Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is significant patient need. Our pipeline consists of two clinical stage compounds, TBR-760 for the treatment of non-functioning pituitary adenoma (NFPA) and TBR-065 for additional rare endocrine diseases. The company was launched out of orphan drug accelerator Cydan with financing from leading life sciences investors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/03/19 | $31,000,000 | Series A |
Alexandria Venture Investments Longitude Capital Lundbeckfonden Ventures New Enterprise Associates | undisclosed |
